Form 4: Jazz Pharmaceuticals Director Jennifer Cook Reports Stock Transactions

Director Jennifer Cook of Jazz Pharmaceuticals reports acquisition and disposal of ordinary shares, including shares sold to cover tax obligations from vesting restricted stock units.

Summary

• On August 2, 2024, Jennifer Cook, a director of Jazz Pharmaceuticals, acquired 3,731 ordinary shares at a price of $0.00.
• These shares were acquired as restricted stock units granted under the company's 2007 Amended and Restated Non-Employee Directors Stock Award Plan, vesting fully on July 25, 2025.
• On August 6, 2024, Cook disposed of 1,484 ordinary shares at a price of $111.35.
• These shares were sold to satisfy tax obligations related to the vesting of previously granted restricted stock units.
• Following these transactions, Cook beneficially owns 9,135 ordinary shares.

Sentiment

Score: 5

Explanation: The document reflects routine transactions related to director compensation and tax obligations, indicating a neutral sentiment.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It reflects standard compensation practices involving stock-based awards and tax obligation management.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine insider trading activity related to compensation.

Key Dates